

CADTH DRUG REIMBURSEMENT REVIEW

Pharmacoeconomic Report

ATEZOLIZUMAB (TECENTRIQ) + BEVACIZUMAB

(Hoffmann-La Roche Limited)

Indication: in combination with platinum-based chemotherapy for the treatment of locally advanced or metastatic non-squamous non-small cell lung cancer in patients with EGFR or ALK genomic tumour aberrations who have progress on treatment with targeted therapies.

Version: Final
Publication Date: July 3, 2020
Report Length: 16 Pages

Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners' own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein are those of CADTH and do not necessarily represent the views of Canada's federal, provincial, or territorial governments or any third party supplier of information.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user's own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian *Copyright Act* and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

About CADTH: CADTH is an independent, not-for-profit organization responsible for providing Canada's health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.

Funding: CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec.

Table of Contents

List of Tables.....	4
Abbreviations	5
Executive Summary	6
Conclusions	8
Stakeholder Input Relevant to the Economic Review.....	9
Economic Review	10
Appendix 1: Cost Comparison Table.....	11
Appendix 2: Submission Quality	12
Appendix 3: Additional Information on the Submitted Economic Evaluation	13
Appendix 4: Additional Details on the CADTH Reanalyses and Sensitivity Analyses of the Economic Evaluation	14
Appendix 5: Additional Information on the Submitted BIA.....	15

List of Tables

Table 1: Submitted for Review.....	6
Table 2: Summary of Economic Evaluation.....	7

Abbreviations

ABCP	atezolizumab bevacizumab carboplatin paclitaxel
ALK	anaplastic lymphoma kinase
BIA	budget impact analysis
CGP	clinical guidance panel
EGFR	epidermal growth factor receptor
ICER	incremental cost-effectiveness ratio
kg	kilogram
KM	Kaplan-Meier
LY	life-year
mg	milligram
mL	milliliter
NOC	notice of compliance
NSCLC	non-small cell lung cancer
OS	overall survival
PFS	progression-free survival
PSM	partitioned survival model
QALY	quality-adjusted life-year

Executive Summary

The executive summary is comprised of two tables: Table 1 Background and Table 2: Economic Evaluation) and a conclusion.

Table 1: Submitted for Review

Item	Description
Drug product	Atezolizumab (Tecentriq), 1200 mg vial for intravenous infusion and bevacizumab, 100 mg or 400 mg vials for intravenous infusion.
Submitted price	Atezolizumab, 1200 mg / 20 mL, intravenous infusion: \$6,776.00 per vial Bevacizumab, 100 mg / 4 mL, intravenous infusion: \$519.18 per vial Bevacizumab, 400 mg / 16 mL, intravenous infusion: \$2,076.71 per vial
Indication	Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of adult patients with metastatic non-squamous NSCLC, with no EGFR or ALK genomic tumour aberrations, and no prior systemic chemotherapy treatment for metastatic non-squamous NSCLC.
Health Canada approval status	NOC
Health Canada review pathway	Standard review
NOC date	May 24, 2019
Reimbursement request	Atezolizumab in combination with bevacizumab and a platinum-based chemotherapy for the treatment of metastatic EGFR and/or ALK positive non-squamous non-small cell lung cancer patients who have progressed on treatment with targeted therapies. Maintenance atezolizumab should be continued until loss of clinical benefit or unacceptable toxicity. Maintenance bevacizumab should be continued until disease progression or unacceptable toxicity.
Sponsor	Hoffmann-La Roche Limited
Submission history	Previously reviewed: No

mg = Milligram; mL = Milliliter; NOC = Notice of Compliance;

Table 2: Summary of Economic Evaluation

Component	Description
Type of economic evaluation	Cost-utility analysis, cost-effectiveness analysis Partitioned survival model
Target population	Patients with locally advanced or metastatic non-squamous NSCLC with EGFR- and/or ALK genomic tumour aberrations (i.e., EGFR or ALK+) who have progressed on treatment with targeted therapies
Treatment	Atezolizumab and bevacizumab in combination with carboplatin and paclitaxel followed by atezolizumab and bevacizumab maintenance
Comparator	Platinum-based chemotherapy in combination with pemetrexed followed by pemetrexed maintenance
Perspective	Canadian publicly funded health care payer
Outcomes	QALYs, LYs
Time horizon	Lifetime (ten years)
Key data source	IMpower150 trial for atezolizumab and bevacizumab treatment efficacy; network meta-analysis (NMA) for comparator treatment efficacy
Submitted results for base case	ICER = \$362,346 per QALY (0.66 QALY, \$239,629 incremental costs)
Key limitations	<ul style="list-style-type: none"> • Uncertainty exists as to the comparative efficacy of ABCP and platinum-based chemotherapy plus pemetrexed. The NMA used data from populations that may not be comparable and excluded key comparators and trials. As a result, the magnitude of clinical benefit with ABCP is highly uncertain. • Several issues were identified with the implementation and extrapolation of the clinical data within the submitted economic evaluation, which included median OS not being reached in the observed period, a long plateau in the OS curve being informed by fewer than 10 participants and the OS and PFS curves crossing. This led to uncertainty with the approximation and extrapolation of the observed data within the model, particularly given much of the benefit observed with ABCP was over the extrapolation period. • A proximity-to-death approach was used to describe patient health states, which is not aligned with the event leading to the largest change in patient utility (i.e., being on or off treatment), nor has this approach been well validated. Additionally, the sponsor excluded adverse event disutilities, the impact of which would not be captured in routine utility questionnaires. • The proportion of patients on each initial therapy receiving subsequent therapy following discontinuation, as well as the distribution of subsequent therapies, was not representative of the Canadian setting, likely overestimating the costs for patients on platinum-based chemotherapy plus pemetrexed. • Biosimilar bevacizumab is less costly than the sponsor submitted price for branded bevacizumab, likely overestimating costs associated with ABCP. Clinical expert feedback indicated biosimilar bevacizumab was likely to be used in clinical practice instead of the branded option.
CADTH reanalysis results	<ul style="list-style-type: none"> • CADTH conducted a reanalysis which included: applying utilities based on patients being on or off treatment, incorporating disutilities for treatment-related adverse events, updating the proportion of patients on subsequent therapy and the distributions of those therapies to be more representative of Canadian clinical practice, and use of the biosimilar price for bevacizumab. Issues related to the comparative efficacy of ABCP could not be addressed, while issues related to the implementation and extrapolation of clinical data were assessed in scenario analyses. • Based on CADTH reanalyses, the ICER = \$430,339 per QALY • At a price reduction of 99% for atezolizumab, the ICER is \$158,883 per QALY gained. It is highly unlikely that ABCP would be considered cost-effective at conventionally accepted ICER thresholds (\$50,000 or \$100,000 per QALY), unless there were significant price reductions for both atezolizumab and bevacizumab.

ALK = anaplastic lymphoma kinase; EGFR = epidermal growth factor receptor; ICER = incremental cost-effectiveness ratio; LY = life-year; NMA = network meta-analysis; NSCLC = non-small cell lung cancer; PSM = partitioned survival model; QALY= quality-adjusted life-year

Conclusions

CADTH undertook reanalyses of the sponsor's economic submission to address some of the identified limitations: applying utilities based on patients being on or off treatment, incorporating disutilities for treatment-related adverse events, updating the proportion of patients on subsequent therapy and the distributions of those therapies to be more representative of Canadian clinical practice, and use of the biosimilar price for bevacizumab. Based on CADTH reanalyses, the ICER for ABCP compared to platinum-based chemotherapy plus pemetrexed was \$430,339 per QALY gained. The results are primarily driven by the combined cost of treatment for bevacizumab and atezolizumab. Even at a 99% price reduction for atezolizumab, the ICER remains over even a \$100,000 per QALY, as the cost of bevacizumab remains high. Along with a 99% price reduction for atezolizumab, the price of biosimilar bevacizumab would need to be approximately 46% below current list price for the ICER to fall below \$100,000 per QALY or approximately 85% to fall below \$50,000 per QALY.

The comparative clinical evidence used to inform this analysis is highly uncertain as there are concerns regarding the magnitude of effect that has been calculated in this analysis, particularly over the extrapolation period.

Overall it is highly unlikely that ABCP would be considered a cost-effective use of Canadian healthcare resources, at a \$50,000 or \$100,000 per QALY threshold, even if substantial price reductions were obtained for both atezolizumab and bevacizumab.

Based on the sponsor's submitted budget impact analysis, the total incremental cost is estimated to be [REDACTED] over the first three years. CADTH reanalyses suggest that the estimated budget impact of introducing ABCP to the market was underestimated, with an estimated incremental cost of \$70,005,616 over three years. *(Non-Disclosable information was used in this pCODR Guidance Report and the sponsor requested this economic information not be disclosed pursuant to the pCODR Disclosure of Information Guidelines. This information will remain redacted until notification by the sponsor that it can be publicly disclosed.)*

Stakeholder Input Relevant to the Economic Review

This section outlines the technical details of the pCODR Economic Guidance Panel's evaluation of the economic evidence that is summarized in the executive summary. In accordance with the *Disclosure of Information Guidelines for the CADTH Pan-Canadian Oncology Drug Review*, this section is not eligible for disclosure. It was provided to the pCODR Expert Review Committee (pERC) for their deliberations and the participating drug programs for their information.

Economic Review

This section outlines the technical details of the pCODR Economic Guidance Panel's evaluation of the economic evidence that is summarized in the executive summary. In accordance with the *Disclosure of Information Guidelines for the CADTH Pan-Canadian Oncology Drug Review*, this section is not eligible for disclosure. It was provided to the pCODR Expert Review Committee (pERC) for their deliberations and the participating drug programs for their information.

Appendix 1: Cost Comparison Table

This section outlines the technical details of the pCODR Economic Guidance Panel's evaluation of the economic evidence that is summarized in the executive summary. In accordance with the *Disclosure of Information Guidelines for the CADTH Pan-Canadian Oncology Drug Review*, this section is not eligible for disclosure. It was provided to the pCODR Expert Review Committee (pERC) for their deliberations and the participating drug programs for their information.

Appendix 2: Submission Quality

This section outlines the technical details of the pCODR Economic Guidance Panel's evaluation of the economic evidence that is summarized in the executive summary. In accordance with the *Disclosure of Information Guidelines for the CADTH Pan-Canadian Oncology Drug Review*, this section is not eligible for disclosure. It was provided to the pCODR Expert Review Committee (pERC) for their deliberations and the participating drug programs for their information.

Appendix 3: Additional Information on the Submitted Economic Evaluation

This section outlines the technical details of the pCODR Economic Guidance Panel's evaluation of the economic evidence that is summarized in the executive summary. In accordance with the *Disclosure of Information Guidelines for the CADTH Pan-Canadian Oncology Drug Review*, this section is not eligible for disclosure. It was provided to the pCODR Expert Review Committee (pERC) for their deliberations and the participating drug programs for their information.

Appendix 4: Additional Details on the CADTH Reanalyses and Sensitivity Analyses of the Economic Evaluation

This section outlines the technical details of the pCODR Economic Guidance Panel's evaluation of the economic evidence that is summarized in the executive summary. In accordance with the *Disclosure of Information Guidelines for the CADTH Pan-Canadian Oncology Drug Review*, this section is not eligible for disclosure. It was provided to the pCODR Expert Review Committee (pERC) for their deliberations and the participating drug programs for their information.

Appendix 5: Additional Information on the Submitted BIA

This section outlines the technical details of the pCODR Economic Guidance Panel's evaluation of the economic evidence that is summarized in the executive summary. In accordance with the *Disclosure of Information Guidelines for the CADTH Pan-Canadian Oncology Drug Review*, this section is not eligible for disclosure. It was provided to the pCODR Expert Review Committee (pERC) for their deliberations and the participating drug programs for their information.

References

1. IMpower150: efficacy of atezolizumab (atezo) plus bevacizumab (bev) and chemotherapy (chemo) in 1L metastatic nonsquamous NSCLC (mNSCLC) across key subgroups. *Oncology research and treatment*. 2018;41(239).
2. Hoffman-La Roche Limited NMA: Network meta-analysis (NMA) and matched-adjusted indirect comparison (MAIC) of interventions for the treatment of patients with stage IV non-squamous non-small cell lung cancer (NSCLC) who have not received prior treatment for stage IV NSCLC. In: pan-Canadian Oncology Drug Review sponsor submission: Tecentriq (atezolizumab) 1200 mg IV every 3 weeks in combination with Avastin (bevacizumab), 15mg/kg IV every 3 weeks. [internal sponsor's submission]. Mississauga (ON): Hoffman-La Roche Limited; 2019 Nov 18.
3. Zinner RG, Obasaju CK, Spigel DR, et al. PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients with advanced nonsquamous non-small-cell lung cancer. *J Thorac Oncol*. 2015;10(1):134-142.
4. Pharmacoeconomic evaluation. In: pan-Canadian Oncology Drug Review manufacturer submission: Tecentriq (atezolizumab) 1200 mg IV every 3 weeks in combination with Avastin (bevacizumab), 15mg/kg IV every 3 weeks. Hoffman-La Roche Limited. Mississauga (ON): Hoffman-La Roche Limited; 2019 Nov 18.
5. Excellence NfHaC. Pembrolizumab for untreated PD-L1-positive 1897 metastatic non-small-cell lung cancer (TA531). 2018: <https://www.nice.org.uk/guidance/ta531/history>. Accessed 20 Dec 2019.
6. DeltaPA. [Ottawa (ON)]: IQVIA; 2019: <https://www.iqvia.com/>. Accessed 1800 Mth Dd.
7. Bank of C. Inflation calculator. 2019; <https://www.bankofcanada.ca/rates/related/inflation-calculator/>. Accessed 1800 Mth Dd.
8. <https://www.nice.org.uk/guidance/ta584/evidence/appraisal-consultation-committee-papers-pdf-6786024445> NfHaCE-. Atezolizumab in combination for treating advanced non-squamous non-small-cell lung cancer [ID1210] 2019.
9. Chiou VL, Burotto M. Pseudoprogression and Immune-Related Response in Solid Tumors. *J Clin Oncol*. 2015;33(31):3541-3543.
10. Woods B, Sideris E, Palmer S, Latimer N, Soares M. NICE DSU Technical Support Document 19: Partitioned Survival Analysis for Decision Modelling in Health Care: A Critical Review. 2017: <http://nicedsu.org.uk/wp-content/uploads/2017/06/Partitioned-Survival-Analysis-final-report.pdf>. Accessed Dec 12 2019.
11. Hess LM, Cui ZL, Li XI, Oton AB, Shortenhaus S, Watson IA. Drug wastage and costs to the healthcare system in the care of patients with non-small cell lung cancer in the United States. *J Med Econ*. 2018;21(8):755-761.
12. Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. *N Engl J Med*. 2017;376(7):629-640.
13. Gandhi L, Rodriguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. *N Engl J Med*. 2018;378(22):2078-2092.
14. Committee CCSA. *Canadian Cancer Statistics 2018*. Toronto, ON: Canadian Cancer Society;2018.